Endothelin: From molecule to man

British Journal of Clinical Pharmacology

Volumn 44, Issue 1, 1997, Pages 9-20

  Webb, D J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PHOSPHORAMIDON; SARAFOTOXIN S6C; TAK 044; THIORPHAN;

ACUTE KIDNEY FAILURE; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CLINICAL PHARMACOLOGY; CONGESTIVE HEART FAILURE; GENE EXPRESSION; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESSOR RESPONSE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SUBARACHNOID HEMORRHAGE; VASOCONSTRICTION;

EID: 0030789622     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00655.x     Document Type: Article

References (84)

1. Anderson J, Williams N. Foresight in science: an experiment in the field of cardiovascular research. Unit for Policy Research in Science and Medicine (PRISM) Report No. 3, 1995, pp. 1-64.
2. Webb DJ, Cumming AMM, Leckie BJ, et al. Reduction of blood pressure in man with H142, a potent new renin inhibitor. Lancet 1983; ii: 1486-1487.
3. Webb DJ, Collier JG. Influence of ramipril diacid on the peripheral vascular effects of angiotensin I. Am J Cardiol 1987; 59: 45D-49D.
4. Benjamin N, Cockcroft JR, Collier JG, Dollery CD, Ritter JM, Webb DJ. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol (Lond) 1989; 412: 543-555.
5. Webb DJ, Cockcroft JR. Circulating and tissue renin-angiotensin systems and the role of the endothelium. pp. 65-80. In The Endothelium: An Introduction to Current Research ed Warren JB. 1990, Alan Liss, New York.
6. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
7. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
8. Clarke JG, Benjamin N, Larkin SW, et al. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 1989; 257: H2033-2035.
9. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 1994; 46: 328-415.
10. Gray GA, Webb DJ. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Pharmacol Ther 1996; 72: 109-148.
11. Ferro CJ, Webb DJ. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs 1996; 51: 12-27.
12. Kiowski W, Sütsch G, Hunziker P, et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-736.
13. Inoue A, Yanagisawa M, Kimura S. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863-2867.
14. Xu D, Emoto N, Giaid A. ECE-1: a membrane-bound metalloprotease that catalyses the proteolytic activation of big endothelin-1. Cell 1994; 78: 473-485.
15. Warner TD, Elliott JD, Ohlstein EH. California dreamin' 'bout endothelin: emerging new therapeutics. Trends Pharmacol Sci 1996; 17: 177-179.
16. Yoshimoto S, Ishizaki Y, Sasaki T, Murota SI. Effect of carbon dioxide and oxygen on endothelial production by cultured porcine cerebral endothelial cells. Stroke 1991; 22: 378-383.
17. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94: 1578-1584.
18. Davenport AP, Maguire JJ. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci 1994; 15: 9-11.
19. Molenaar P, O'Reilly G, Sharkey A, et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circulation 1993; 72: 526-538.
20. Hosoda K, Nakao K, Hirosh-Arai, et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991; 287: 23-26.
21. Ogawa Y, Nakao K, Arai H, et al. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 1991; 178: 248-255.
22. Bax WA, Saxena PR. The current endothelin receptor classification: time for reconsideration? Trends Pharmacol Sci 1994; 15: 379-386.
23. Clozel M, Loffler BM, Breu V, Hilfiger L, Maire JP, Butscha B. Downregulation of endothelin receptors by autocrine production of endothelin-1. Am J Physiol 1993; 265: 188-192.
24. Liu J, Chen R, Casley DJ, Nayler WN. Ischaemia and reperfusion increase 125-I labelled endothelin-1 binding in rat cardiac membranes. Am J Physiol 1990; 258: H828-H835.
25. Nambi P, Pullen M, Contino LC, Brooks DP. Upregulation of renal endothelin receptors in rats with cyclosporin-A induced nephrotoxicity. Eur J Pharmacol 1990; 187: 113-116.
26. Newman P, Kakkar VV, Kanse SM. Modulation of endothelin receptor expression in human vascular smooth muscle cells by interleukin-1 beta. FEBS Lett 1995; 363: 161-164.
27. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Macmura K, Nagai R. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368: 703-710.
28. Kurihara Y, Kurihara H, Oda H, et al. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest 1995; 96: 293-300.
29. Ong ACM. Surprising new roles for endothelins. Br Med J 1996; 312: 195-196.
30. Hosoda K, Hammer RE, Richardson JA, et al. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 1994; 79: 1267-1276.
31. Puffenberger EG, Hosoda K, Washington SS, et al. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 1994; 79: 1257-1266.
32. Attié T, Pelet A, Edery P, et al. Mutation of the endothelin-receptor B gene in the Waardenburg-Hirschsprung disease. Hum Mol Genet 1995; 4: 2407-2409.
33. Vierhapper HO, Wagner P, Nowotny P, Walhausl W. Effect of endothelin in man. Circulation 1990; 81: 1415-1418.
34. Pernow J, Kaijser L, Lundberg JM, Ahlborg G. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996; 94: 2077-2082.
35. Wagner OF, Vierhapper H, Gasic S, Nowotny P, Waldhausl W. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest 1992; 22: 277-282.
36. Weiser E, Wollberg Z, Kochva E, Lee Y. Cardiotoxic effects of the venom of the burrowing asp, Actractaspis engaddensis (Actractaspididae, Ophidia). Toxicon 1984; 22: 767-774.
37. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995; 25: 918-923.
38. Webb DJ. The pharmacology of human blood vessels in vivo. J Vasc Res 1995; 32: 2-15.
39. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995; 92: 357-363.
40. Yang Z, Richard V, von Segesser I. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism for vasospasm? Circulation 1990; 82: 188-195.
41. Cockcroft JR, Clarke JG, Webb DJ. The effect of intra-arterial endothelin on resting blood flow and sympathetically mediated vasoconstriction in the forearm of man. Br J Clin Pharmacol 1991; 31: 521-524.
42. Haynes WG, Hand MF, Johnstone HA, Padfield PL, Webb DJ. Direct and sympathetically mediated venoconstriction in essential hypertension: enhanced response to endothelin. J Clin Invest 1994; 94: 1359-1364.
43. Haynes WG, Webb DJ. Endothelium dependent modulation of responses to endothelin-1 in human hand veins. Clin Sci 1993; 84: 427-433.
44. Haynes WG, Webb DJ. Venoconstriction to endothelin-1 in humans: the role of calcium and potassium channels. Am J Physiol 1993; 265 (Heart Circ. Physiol. 34): H1676-81.
45. Opgenorth T, Wu Wong JR, Shiosaki K. Endothelin-converting enzymes. FASEB J 1992; 6: 2653-2659.
46. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344: 852-854.
47. Plumpton C, Haynes WG, Webb DJ, Davenport AP. Phosphoramidon inhibition of the in vivo conversion of big endothelin to endothelin-1 in the human forearm. Br J Pharmacol 1995; 116: 1821-1828.
48. Watanabe Y, Naruse M, Monzen C, et al. Is big endothelin converted to endothelin-1 in circulating blood? J Cardiovasc Pharmacol 1991; 17 (Suppl 7): S503-S505.
49. Haynes WG, Moffat S, Webb DJ. An investigation into the direct and indirect venoconstrictor effects of endothelin-1 and big endothelin-1 in man. Br J Clin Pharmacol 1995; 40: 307-311.
50. Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men: effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995; 26: 1160-1166.
51. A receptor. Life Sci 1992; 50: 247-255.
52. B. Biochem Biophys Res Commun 1994; 200: 1708-1712.
53. Haynes WG, Ferro CJ, O'Kane KPJ, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man. Circulation 1996; 93: 1860-1870.
54. de Berrazueta JR, Bhagat K, Vallance P, MacAllister RJ. Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol 1997: 44, in press.
55. Ishikawa K, Ihara M, Noguchi K, et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 1994; 91: 4892-4896.
56. Love MP, Ferro CJ, Haynes WG, Webb DJ, McMurray JJ. Selective or non-selective endothelin receptor blockade in chronic heart failure? Circulation 1996; 94(suppl I): 2899-2900.
57. Wenzel RR, Noll G, Luscher TF. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994; 23: 581-586.
58. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; ii: 997-1000.
59. Haynes WG, Noon JP, Walker BR, Webb DJ. L-NMMA increases blood pressure in man. Lancet 1993; 342: 931-932.
60. B-mediated blood pressure responses in rats. J Pharmacol Exp Ther 1994; 270: 728-733.
61. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
62. Zeiher AM, Ihling C, Pistorius K, Schachinger V, Schaefer H-E. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994; 344: 1405-1406.
63. Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA 1995; 92: 5244-5248.
64. Dubin D, Pratt RE, Dzau VJ. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vasc Med Biol 1989; 1: 150-154.
65. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993; 14: 385-399.
66. Dargie HJ, McMurray JJV. Diagnosis and management of heart failure. Br Med J 1994; 308: 321-328.
67. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985; 72: 406-412.
68. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384: 353-355.
69. Omland T, Lie RT, Aakvaag A. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-1579.
70. Pacher R, Bergler-Klein J, Globits S, et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993; 71: 1293-1299.
71. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-509.
72. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Importance of endothelin in the exercise intolerance of heart failure in humans. Mayo Clin Proc 1992; 67: 719-724.
73. Galatius-Jensen S, Wroblewski H, Emmeleuth C, Bie P, Haunso S, Kastrup J. Plasma endothelin-1 in chronic heart failure: a predictor of cardiac death? Circulation 1994; 90: 379.
74. Pacher R, Stanek B, Hülsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27: 633-641.
75. Krum H, Gu A, Wilshire Clement M, Sackner Bernstein J, Goldsmith R. Changes in plasma endothelin-1 levels reflect clinical response to beta blockade in chronic heart failure. Am Heart J 1996; 131: 337-341.
76. Webb DJ. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure: endothelin antagonism in heart failure. Circulation 1995; 92: 3372.
77. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJV. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996; 94: 2131-2137.
78. Love MP, Haynes WG, Webb DJ, McMurray JJ. Endothelin receptor function in capacitance vessels of patients with chronic heart failure. Circulation 1996; 94(suppl I): 2899-2900.
79. Cannan CR, Burnett JC Jr, Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation 1996; 93: 646-651.
80. Dagassan PH, Breu V, Clozel M, et al. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 1996; 27: 147-153.
81. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Medicine 1995; 9: 944-949.
82. B receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat. J Cardiovasc Pharmacol 1995; 26(suppl 3): S169-S176.
83. B receptors in rats. Biochem Biophys Res Commun 1994; 199: 1461-1465.
84. Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 1996; 119: 311-314.